Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
  • Patent number: 11857678
    Abstract: The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: January 2, 2024
    Assignee: Benuvia Operations, LLC
    Inventors: Kiran Kumar Vangara, Thrimoorthy Potta, Venkat Goskonda
  • Patent number: 11826428
    Abstract: The present specification discloses solid solution pharmaceutical compositions comprising hard fats, liquid lipids, and one or more cannabidiols, including a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: November 28, 2023
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 11779563
    Abstract: Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders using the oral cannabinoid pharmaceutical compositions are described.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: October 10, 2023
    Assignee: Curio IP, LLC
    Inventors: Edward M. Rudnic, Michael Bronfein
  • Patent number: 11752127
    Abstract: The present technology relates to a method for treating anxiety or an anxiety-related disorder in an animal subject, the method comprising administering an effective amount of cannabidiol (CBD) to the animal subject.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 12, 2023
    Assignee: VIRBAC CORPORATION
    Inventors: Justyna Kulpa, Dana M. Vaughn
  • Patent number: 11730715
    Abstract: The disclosure provides compositions comprising cannabinoids and active ingredients and/or excipients and methods of producing the compositions.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: August 22, 2023
    Assignee: Nuka Enterprises
    Inventors: Erin Holzer, Peter Barsoom, Justin Kirkland
  • Patent number: 11590230
    Abstract: Provided is a composition for oral administration which includes a lipophilic active substance and a phospholipid, providing a prolonged therapeutic effect.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: February 28, 2023
    Inventor: Elka Touitou
  • Patent number: 11590083
    Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: February 28, 2023
    Assignee: Therabiome, LLC
    Inventors: Mohan Kabadi, Jerome J. Schentag
  • Patent number: 11583498
    Abstract: The invention relates to a process for producing a Tan IIA nanoliposome system for foods and medical products, comprises: (i) preparing a dispersed phase by dissolving Tan IIA in ethanol in a Tan IIA weight:ethanol volume ratio of 8:10 by a stirrer at 300-500 rpm with heating to 40-60° C. within 4-8 hours; (ii) preparing a liposome carrier consisting of lecithin and olive oil in a ratio of 1:3 by weight by mixing in a constant temperature bath at 40-60° C. to ensure that lecithin is completely dissolved in the oil while stirring; (iii) adding the carrier to the dispersed phase in a ratio of 40:60 by weight, further heating the carrier and dispersed phase mixture to 40-60° C. and stirring at 800-1000 rpm within 1 to 2 hours; (iv) cooling the resulting mixture to 25° C. and pumping the cooled mixture, using an ultrasonic atomizer nozzle at 60 Hz (10-20 ?m droplet size, 10 mL/min), into 1-1.5 L of distilled water (with the temperature of the distilled water at 25° C.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: February 21, 2023
    Assignee: WAKAMONO CORPORATION
    Inventors: Hong Ngoc Thi Dang, Nam Hai Lai
  • Patent number: 11571392
    Abstract: Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 7, 2023
    Assignee: Rhodes Pharmaceuticals L.P.
    Inventor: Robert J. Kupper
  • Patent number: 11560365
    Abstract: A novel non-fluorescent rhodamine dye forms a twisted intramolecular charge transfer state. A substituent that causes steric hindrance is introduced at an ortho position of a dimethylamino group on the xanthene ring of tetramethylrhodamine, which is a general rhodamine that exhibits strong fluorescence, and a certain amount of twist is imparted in a ground state. As a result, the formation of the twisted intramolecular charge transfer state is promoted in the excited state and non-fluorescence is exhibited.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 24, 2023
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Kenjiro Hanaoka, Yasuteru Urano, Takayuki Ikeno
  • Patent number: 11541030
    Abstract: The present invention provides methods of treating inflammation associated with infection, and methods of preventing or reducing the severity of sepsis caused by inflammation associated with infection, in an individual comprising, consisting essentially of or consisting of the steps of administering a therapeutically effective amount of idronoxil, or derivative, pharmaceutically acceptable salt, ester, amide, polymorph and/or prodrug thereof to the individual, wherein the individual is diagnosed with, or suspected of having, early stage organ damage caused by inflammation associated with infection.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: January 3, 2023
    Assignee: NOXOPHARM LIMITED
    Inventors: Graham Kelly, Olivier Laczka, Michael Gantier
  • Patent number: 11529320
    Abstract: The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: December 20, 2022
    Assignee: Phytecs, Inc.
    Inventors: Tamas Biro, Ethan B. Russo
  • Patent number: 11510897
    Abstract: This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: November 29, 2022
    Assignee: CANOPY GROWTH CORPORATION
    Inventor: Kurt Aron Levy
  • Patent number: 11497727
    Abstract: A method of producing a cannabinoid nanoparticle carrier composition for administration to a human, including the steps of incorporating non-ionic surfactants with cannabinoid oils and lipids; inducing sonication for a predetermined period of time at a predetermined amplification with a ultrasonic liquid processor until completely integrated; dissolving ascorbic acid into a carrier fluid; combining in sequence the non-ionic surfactants, lipids, and cannabinoids with a carrier fluid consisting of distilled water and ascorbic acid; sonicating using an ultrasonic liquid processor at predetermined amplitude for a predetermined period of time at a controlled temperature.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: November 15, 2022
    Inventor: Aaron Miles
  • Patent number: 11478446
    Abstract: The present invention relates to a topically administered cannabinoid formulation that is particularly well suitable for relieving or reducing muscle, joint, and nerve pain. The formulation can be easily and painlessly applied to painful areas, and is rapidly absorbed. The formulation also comprises one or more essential oils having analgesic properties and menthol. The topical emulsified creams and lotions may comprise a full spectrum of cannabis compounds, including THC and CBD.
    Type: Grant
    Filed: August 28, 2020
    Date of Patent: October 25, 2022
    Inventor: Teresa Ann Hanlon
  • Patent number: 11471405
    Abstract: The present invention relates to a tableted chewing gum composition for oral administration of cannabinoids, the composition comprising water-soluble chewing gum ingredients and water-insoluble gum base located in a plurality of particles, wherein the chewing gum composition comprises one or more cannabinoids, and wherein the chewing gum composition generates saliva and delivers more than 20% by weight of the one or more cannabinoids to the oral mucosa during the first 5 minutes of chewing.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 18, 2022
    Assignee: NordicCan A/S
    Inventors: Heidi Ziegler Bruun, Dorthe Schackinger Boesen, Ane Eriksen
  • Patent number: 11472786
    Abstract: Disclosed herein is a method of converting a THC-rich cannabinoid mixture that comprises at least about 20% THC into a CBN-rich cannabinoid mixture that comprises at least about 2.0% CBN. The method comprises contacting the cannabinoid mixture with a benzoquinone reagent under reaction conditions comprising: (i) a reaction temperature that is within a target reaction-temperature range; and (ii) a reaction time that is within a target reaction-time range, such that at least a portion of the of the THC in the THC-rich cannabinoid mixture is converted into CBN.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: October 18, 2022
    Assignee: Canopy Growth Corporation
    Inventors: Christopher Adair, Mahmood Azizpoor Fard, Ben Geiling, Mohammadmehdi Haghdoost Manjili
  • Patent number: 11446278
    Abstract: A topical composition includes a cannabinoid, a terpenoid, and a skin penetration system that includes dimethyl sulfoxide (DMSO) and at least one compatibilizer. The composition may be in the form of an emulsion that further contains water and at least one fatty component. The composition can be used to reduce or eliminate pain by topical application to an affected region of the body. The composition provides localized pain relief by providing a focused quantity of cannabinoid in the region of the pain instead of distributing the cannabinoid systemically and/or delivering it to the brain or central nervous system.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: September 20, 2022
    Assignee: TECH SWERVE LLC
    Inventor: John M. Guynn
  • Patent number: 11413266
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 16, 2022
    Assignee: GW Pharma Limited
    Inventors: Tamás Biró, Colin Stott, Vincenzo Di Marzo
  • Patent number: 11400055
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: August 2, 2022
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele
  • Patent number: 11358945
    Abstract: The present invention discloses a method for preparing a cyclopenta[c]chromene compound. A cationic rare earth compound [Ln(CH)3CN)9]3+[(AlCl4)3]3?.CH3CN is used as a catalyst, and p-methyl thiophenol is used as an accelerator for a catalytic reaction of a chalcone compound so as to prepare a product; and Ln, contained in the catalyst, represents a positive trivalent rare earth metal ion and is selected from one of La, Nd, Sm, Gd and Yb. According to the method, the starting materials are easy to obtain, the reaction process is simple, the catalyst usage is low, the catalyst is universally applicable to various substituted 2-hydroxy chalcones, and the obtained cyclopenta[c]chromene compound has not been reported. The catalyst synthesis method is simple and easy to obtain, and the yield of the target product is high.
    Type: Grant
    Filed: January 31, 2021
    Date of Patent: June 14, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Fan Xu, Dandan Li, Xiaoyou Ding, Yanan Zhu, Zhigang Yao
  • Patent number: 11351212
    Abstract: A method for drying to increase the useful life of botanicals and shorten the time to market after harvest of the botanicals. The method may include flash freezing the botanicals, at a desired optimal temperature range, soon after harvest. The method may include storing the frozen botanicals indefinitely prior to drying. The method may include drying the frozen botanicals using a lyophilizer at a desired optimal temperature and pressure.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: June 7, 2022
    Inventor: Eric Young
  • Patent number: 11331279
    Abstract: The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: May 17, 2022
    Assignee: RADIUS PHARMACEUTICALS, INC.
    Inventors: Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
  • Patent number: 11332475
    Abstract: The present invention relates to pyranochromenylphenol derivatives having different efficacies depending on the direction of optical activity and a pharmaceutical composition including the same, and in the pyranochromenylphenol derivatives, an R-enantiomer has excellent anti-diabetic efficacy by suppressing a rise in blood sugar and an S-enantiomer has excellent anti-obesity efficacy by suppressing an increase in body weight.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: May 17, 2022
    Inventors: Sang Ku Yoo, Jin Wook Chung, In Geun Jo, Ji Young Kim, Jeong Ho Im, Ku Suk Kang, Jin Young Kim
  • Patent number: 11304925
    Abstract: The invention relates to a method for treating cancer or a symptom associated with cancer. In particular, the present invention relates to a method for treating cancer or a symptom associated with cancer, comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition comprising a Cannabis extract that comprises ?9-tetrahydrocannabinol (THC) in an amount of from 50% to 99% by weight of the pharmaceutical composition.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: April 19, 2022
    Assignee: ZELDA THERAPEUTICS OPERATIONS PTY LTD
    Inventors: Harry Karelis, Mara Gordon, Stewart Smith, Stewart Washer
  • Patent number: 11291631
    Abstract: The present invention relates to a cannabinoid containing oral solution. Preferably the oral solution comprises a cannabinoid, a lipid solvent, a sweetener and ethanol, characterised in that the sweetener is an ultrahigh potency sweetener.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: April 5, 2022
    Assignee: GW Research Limited
    Inventor: Harshit Shah
  • Patent number: 11260043
    Abstract: This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: March 1, 2022
    Assignee: SUTTER BAY HOSPITALS
    Inventors: Sean D. McAllister, Pierre-Yves Desprez
  • Patent number: 11260044
    Abstract: Described are methods of modulating the activation of the TRPV1 ion channel by administering at least one cannabinoid and/or terpene compound.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 1, 2022
    Assignee: GBS GLOBAL BIOPHARMA, INC.
    Inventors: Andrea Small-Howard, Helen Turner
  • Patent number: 11246852
    Abstract: Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: February 15, 2022
    Assignee: Receptor Holdings, Inc.
    Inventors: Andrea Leone-Bay, Gregory Wesner
  • Patent number: 11234956
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: February 1, 2022
    Assignee: SciSparc Ltd.
    Inventors: Ascher Shmulewitz, Elran Haber, Ephraim Brener
  • Patent number: 11224659
    Abstract: The present specification discloses solid solution pharmaceutical compositions comprising therapeutic compound comprising a phytocannabinoid, an endocannabinoid, a synthetic cannabinoid, or a combination thereof, one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition, and one or more pharmaceutically-acceptable liquid lipids in an amount of less than 45% by weight of the pharmaceutical composition, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: January 18, 2022
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
  • Patent number: 11197846
    Abstract: The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: December 14, 2021
    Assignee: Pleopharma L.L.C.
    Inventor: Ginger D. Constantine
  • Patent number: 11166935
    Abstract: A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing an amount of one or more cannabinoids. Also, pouches for use as a medicament, for use in alleviation of pain, and for use in mitigation of appetite deficiency are disclosed. Further, a method of alleviation of pain and a method of mitigation of appetite deficiency using the pouch are disclosed.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 9, 2021
    Inventor: Heidi Ziegler Bruun
  • Patent number: 11154515
    Abstract: The disclosure describes compositions comprising beta-caryophyllene (BCP) and cannabidiol (CBD). The disclosure also describes compositions which further introduce low levels of THC. The disclosure further describes methods of making and using said compositions, including for the treatment of chronic pain, neurological disorders including epilepsy, addiction and inflammatory skin conditions. The disclosure further describes the use of fluorinated-CBD derivatives for treating inflammatory skin conditions.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: October 26, 2021
    Assignee: Phytecs, Inc.
    Inventors: Tamas Biro, Ethan B. Russo
  • Patent number: 11135445
    Abstract: A problem of incomplete inhibition of harmful cells/bacteria and short duration of time, after the photodynamic treatment, during which such cells may re-grow, is solved by exposing the target bacteria with a multi-component photosensitizer material formed by adding a predetermined potentiating chemical to a conventional single-component photosensitizer at the target, prior to irradiating the target with light. The multi-component photosensitizer is effectuated by forming a mix of the two chemical compositions or by sequential exposure of the bacteria to a single-component photosensitizer and the potentiating chemical of choice.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 5, 2021
    Assignee: The General Hospital Corporation
    Inventors: Daniela Vecchio, Michael R. Hamblin, Yingying Huang, Liyi Huang, Giacomo Landi, Jeffrey A. Gelfand, Timothy Brauns
  • Patent number: 11116210
    Abstract: Health concerns of the vector-borne diseases, such as, yellow fever, malaria, dengue fever and general discomfort due to insect bites, has encouraged the development of insecticides to kill insects and insect repellents to keep insects away from treated human skin. Annatto extracts as a natural insect repellent and insecticide have many advantages over synthetic such as lower harmful side effects, low resistance, and more environmentally friendly. Annatto extracts containing ishwarane (C15) and geranyl-?-terpinene (C20) have strong mosquito repellency. Annatto extracts containing geranyl-?-terpinene (C20) and geranylgeraniol (C20) have strong larvicidal activity. Annatto extracts with approximately equal C15 and C20 composition have insect repellency, and annatto extracts with mainly C20 composition have larvicidal activity. Annatto extracts have synergistic effects with other natural extracts.
    Type: Grant
    Filed: November 10, 2018
    Date of Patent: September 14, 2021
    Assignee: AMERICAN RIVER NUTRITION, LLC
    Inventors: Barrie Tan, Jia Zhang
  • Patent number: 10993928
    Abstract: Various aspects of this patent document relate to liquid compositions comprising cannabidiol, which have either freezing points or glass-liquid transition temperatures less than the melting point of pure cannabidiol.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: May 4, 2021
    Assignee: Natural Extraction Systems, LLC
    Inventor: Nixon Malcolm
  • Patent number: 10981856
    Abstract: A cannabis infused oil is formed by collecting and drying raw cannabis material having a desired cannabinoid profile. Next, the raw dried cannabis material is blended with oil to obtain a cannabis infused oil mixture. Blending is performed without causing the cannabis material to become decarboxylated. Next, the cannabis material is filtered from the cannabis infused oil mixture thereby obtaining a cannabis infused oil. The cannabis infused oil has at least two cannabinoids present in the oil in accordance with the desired cannabinoid profile. Next, the cannabis infused oil is packaged for storage and shipment. The cannabis infused oil is formed without any alcohol, does not have any decarboxylated cannabinoids and is non-psychoactive. In one example, the cannabis infused oil has between 100 milligrams and 2,000 milligrams of cannabinoids per fluid ounce of cannabis infused oil. In another example, before blending with oil, the cannabis material is combined with alcohol.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 20, 2021
    Inventor: Jeff Nordahl
  • Patent number: 10973255
    Abstract: Methods and apparatuses for the customization of tobacco and Cannabis smoking products including formulations for onserts, precision rods and precision pods for harm reduction products particularly for those who simultaneously smoke or vape tobacco and marijuana, as well as methods and apparatuses for blending a salt of nicotine in crystalline form and one or more cannabinoids in crystalline form for a precision pod for use in a vaporizer.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: April 13, 2021
    Assignee: CABBACIS LLC
    Inventor: Joseph Pandolfino
  • Patent number: 10968196
    Abstract: Compounds are provided that are useful in treating cancer and neurodegeneration. The compounds comprise a ?-lapachone or ?-lapachone derivative tricyclic ortho-naphthoguinone moiety linked to a mitochondria-targeting moiety, for example as defined with respect to Formula (I): or a pharmaceutically-acceptable salt thereof. Pharmaceutical compositions are provided comprising the composition. Methods of treatment of cancer and neurodegenerative disorders also are provided.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: April 6, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Chaemin Lim, Wei Qian, Bennett Van Houten
  • Patent number: 10945982
    Abstract: A composition for and method of practicing nasal hygiene to wash and moisturize the nasal passage. Where the nasal wash comprises a liquid homogenized compound of water, chlorine dioxide (or source thereof), olfactory stimulants, unsaturated fatty acids, inorganic salt, fixing agents. Where the unsaturated fatty acid component comprises from 0.1% to 3% by weight of the compound.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: March 16, 2021
    Inventor: Paul A. Lobel
  • Patent number: 10925852
    Abstract: Provided herein are compositions and methods for treatment of a disease, disorder, or condition, such as a proliferative disease, disorder, or condition. One aspect provides a composition including a therapeutic agent and a substrate. Another aspect provides methods for treating a disease, disorder, or condition.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: February 23, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Robert Norman Taub
  • Patent number: 10864458
    Abstract: The present specification discloses methods of purifying one or more cannabinoids from a plant material, purified cannabinoids and pharmaceutical compositions comprising one or more cannabinoids produced by the disclosed method, methods and uses for treating a disease or condition employing such purified cannabinoids and pharmaceutical compositions.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: December 15, 2020
    Assignee: PHYTOPLANT RESEARCH S.L.
    Inventor: Xavier Nadal Roura
  • Patent number: 10857107
    Abstract: Provided herein are cannabinoid-containing complex mixtures suitable for use as active pharmaceutical ingredients. The complex mixtures are comprised of the major cannabinoid, cannabidiol, a first minor cannabinoid, which is cannabigerol, at least a first selected terpene, and optionally a second minor cannabinoid. Also provided are methods of making the complex mixtures, pharmaceutical compositions comprising the complex mixture, and methods of using the pharmaceutical compositions for the treatment of mast cell-related immune disorders, including allergy and atopy (allergic asthma, eczema, rhinitis), mast cell activation syndrome (MCAS), physical and chemical urticarias, idiopathic urticaria, Crohn's disease, inflammatory bowel disorder, dermatitis and contact dermatitis, arthritis and rheumatoid arthritis, canine mastocytosis, and allergy and inflammation in cattle, swine, etc. The methods of the present invention further relate to the treatment of various basophil-mediated immune disorders.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: December 8, 2020
    Assignee: GBS Global BioPharma, Inc.
    Inventors: Andrea Small-Howard, Helen Turner
  • Patent number: 10842773
    Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: November 24, 2020
    Assignee: Canopy Growth Corporation
    Inventor: Kurt Aron Levy
  • Patent number: 10814248
    Abstract: A system, machines and methods for extracting select moieties, flavonoids, and essential oils from plant material without co-extracting chlorophyll, lipids and other undesirable constituents from plants. Super-cooled extraction techniques are taught. Likewise, according to embodiments methods provides 100% grain ethyl alcohol extract with a concentration of chlorophyll that is below 1%.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: October 27, 2020
    Assignee: Capna IP Capital, LLC
    Inventor: Yevgeniy Galyuk
  • Patent number: 10765643
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 8, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10758481
    Abstract: Single-serve containers for use in brewing a cannabis-based beverage are described, as are methods for preparing a single-serve container configured for receipt in a single-serve brewing machine. The method includes: adding a processed cannabis product to the single-serve container; adding, to the single-serve container, at least one of an extraction or flavoring agent; and sealing the single-serve container.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: September 1, 2020
    Assignees: CannTrust Inc., Single Dose Solutions Inc.
    Inventors: Ronald Stuart Benson, Peter Hobbes, Claudio Gemmiti, Ilana Deborah Platt
  • Patent number: 10722490
    Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: July 28, 2020
    Assignee: Canopy Growth Corporation
    Inventor: Kurt Aron Levy
  • Patent number: 10716819
    Abstract: Food grade cannabis extracts and methods for their preparation that may reduce or eliminate the anxiety effect that cannabis may have on a user. Embodiments of the methods include providing raw botanical material; providing food grade glycerin; combining the botanical material with the glycerin; blending the botanical material and the glycerin to achieve a homogenous mixture; optionally pre-heating the mixture prior to being agitated; placing the mixture in a sealable container; providing an agitator; securing the container on or within the agitator, agitating the mixture and allowing the mixture to rest at various intervals; heating the mixture and allowing the mixture to cool at various intervals; straining the mixture; pressing the mixture; and then filtering the mixture to remove any remaining particulates to thereby produce a food grade cannabis extract suitable for at least medical use.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: July 21, 2020
    Assignee: Yabuwi, Inc.
    Inventor: Daniel Hartman Stoops